<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01948648</url>
  </required_header>
  <id_info>
    <org_study_id>B2013:075</org_study_id>
    <nct_id>NCT01948648</nct_id>
  </id_info>
  <brief_title>Effects of Fish Oil and Colesevelam (STAIR7007)</brief_title>
  <official_title>Effects of Fish Oil, Colesevelam and Combination Therapy on Sterol Metabolism in Sitosterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      If treatment of colesevelam, fish oil in conjunction with ezetimibe, will lead to further
      reduction in plasma plant sterol levels in sitosterolemia patients. We hypothesize that
      treatments with fish oil, colesevelam and ezetimibe will maximize decrease in plasma
      concentrations of sitosterol and other plant sterols in sitosterolemia patients.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 6, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma plant sterol level</measure>
    <time_frame>32 weeks</time_frame>
    <description>plasma plant sterol assessment using Gas Chromatography(GC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fatty acid</measure>
    <time_frame>32 weeks</time_frame>
    <description>use of gas chromatography technique to measure fish oil intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endothelial functions</measure>
    <time_frame>32 weeks</time_frame>
    <description>use of EndoPAT 2000 system to assess endothelial function</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Sitosterolemia</condition>
  <arm_group>
    <arm_group_label>Colesevelam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3.75g/day for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fish Oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1g/day for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination of Fish Oil and Colesevelam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3.75g/day of colesevelam and 1g/day of fish oil for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colesevelam</intervention_name>
    <description>Drug is in powder form, each packet contains 3.75g of colesevelam hydrochloride. Participant will mixed it with water and have 1 packet per day during the treatment session.</description>
    <arm_group_label>Colesevelam</arm_group_label>
    <other_name>Lodalis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish Oil</intervention_name>
    <description>In softgel form, contains 660mg EPA and 330mg DHA. Participant consume 1 softgel per day during treatment session.</description>
    <arm_group_label>Fish Oil</arm_group_label>
    <other_name>Omega-3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination of fish oil and colesevelam</intervention_name>
    <description>combination of both colesevelam and fish oil. Participant will consume 1 packet and 1 softgel per day during treatment session.</description>
    <arm_group_label>Combination of Fish Oil and Colesevelam</arm_group_label>
    <other_name>Omega-3 and Lodalis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed diagnosis of homozygous sitosterolemia as established by genotyping and/or
             clinical parameters

          2. Receiving ezetimibe treatment

          3. Over 8 years of age (no maximum)

          4. Concomitant illnesses or conditions

        Exclusion Criteria:

          1. Pregnancy

          2. Intellectual disability

          3. Bowel or biliary obstruction

          4. Known hypersensitivity to colesevelam or any ingredients of colesevelam
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Richardson Center for Functional Foods and Nutraceuticals</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 6, 2013</study_first_submitted>
  <study_first_submitted_qc>September 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2013</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>plant sterols</keyword>
  <keyword>cholesterol</keyword>
  <keyword>colesevelam</keyword>
  <keyword>phytosterolemia</keyword>
  <keyword>fish oil</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colesevelam Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

